JP2021530541A5 - - Google Patents
Info
- Publication number
- JP2021530541A5 JP2021530541A5 JP2021503108A JP2021503108A JP2021530541A5 JP 2021530541 A5 JP2021530541 A5 JP 2021530541A5 JP 2021503108 A JP2021503108 A JP 2021503108A JP 2021503108 A JP2021503108 A JP 2021503108A JP 2021530541 A5 JP2021530541 A5 JP 2021530541A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| US62/711,051 | 2018-07-27 | ||
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530541A JP2021530541A (ja) | 2021-11-11 |
| JP2021530541A5 true JP2021530541A5 (enExample) | 2022-08-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503108A Pending JP2021530541A (ja) | 2018-07-27 | 2019-07-26 | てんかんの治療方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| EP3999570A1 (en) * | 2019-07-18 | 2022-05-25 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ATE199829T1 (de) * | 1994-06-03 | 2001-04-15 | Thejmde Trust | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| DK3261640T3 (da) * | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown